Alkeon Capital Management
EPZM

Alkeon Capital Management’s Epizyme, Inc EPZM Stock Holding History

Alkeon Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-45,000
Closed -$799K – 137
2018
Q1 		$799K Buy
+45,000
New +$760K ﹤0.01% 115

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alkeon Capital Management's EPZM Position: Q2 2018 in Review

Alkeon Capital Management sold out of Epizyme, Inc (EPZM) in Q2 2018, closing a stake of 45,000 shares — an estimated $799K sold.

Alkeon Capital Management first reported a position in EPZM in Q1 2018 and held it in 1 quarter. The position peaked at $799K in Q1 2018. 109 funds tracked by Wall St. Rank hold EPZM as of Q2 2018.

  • Alkeon Capital Management reported no remaining Epizyme, Inc position as of Q2 2018 after selling out during the quarter.
  • Alkeon Capital Management sold 45,000 Epizyme, Inc shares in Q2 2018, an estimated $799K.
  • Alkeon Capital Management first reported a position in Epizyme, Inc in Q1 2018 and held it in 1 quarter.
  • Alkeon Capital Management's Epizyme, Inc position peaked at $799K in Q1 2018.
  • 109 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2018.

Based on Alkeon Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.